Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes (SOHO 2026) - Sep 1, 2026 - Abstract #CML-913; Location: LEVEL 3, HALL B3; "The primary end point was disease progression between days 90 and 270, defined as escalation to ponatinib or omacetaxine, hematopoietic stem cell transplantation, or transformation to acute leukemia. The progression difference did not reach statistical significance, partly reflecting insufficient power to detect a moderate effect. Retrospective claims-level ascertainment of progression is imperfect, as some therapy switches may not represent true disease advancement. The cytopenia reduction with asciminib was substantial and statistically significant."
Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCR
|
|
Ecem Kalemoglu MD PhD 1; Ali Turunc MD 2; Arunabh Sekhri MD 1
|